Cynata Therapeutics Limited is an Australian company that specializes in developing stem cell technology for human therapeutic use. The company's proprietary Cymerus brand is used in its lead product candidate CYP-001, which has completed a Phase I clinical trial for the treatment of graft versus host disease. Cynata also has a Phase III clinical trial for the treatment of osteoarthritis with CYP-004. The company's preclinical models also include treatments for asthma, heart attack, diabetic wounds, and more. Cynata has a strategic partnership with Fujifilm to provide manufacturing and supply services for its products. The company was founded in 2011 and is headquartered in Cremorne, Australia.
Cynata Therapeutics Limited's ticker is CYP
The company's shares trade on the ASX stock exchange
They are based in Cremorne, Australia
There are 1-10 employees working at Cynata Therapeutics Limited
It is https://www.cynata.com/
Cynata Therapeutics Limited is in the Healthcare sector
Cynata Therapeutics Limited is in the Biotechnology industry
The following five companies are Cynata Therapeutics Limited's industry peers: